Apo-Amisulpride New Zealand - English - Medsafe (Medicines Safety Authority)

apo-amisulpride

apotex nz ltd - amisulpride 100mg;   - tablet - 100 mg - active: amisulpride 100mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

APO-Amisulpride 100 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-amisulpride 100 mg tablet blister pack

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

AMISULPRIDE 100 WINTHROP amisulpride 100 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amisulpride 100 winthrop amisulpride 100 mg tablet blister pack

sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; hypromellose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.